Fortress Reports Positive Data And Other News: The Good, Bad And Ugly Of BiopharmaSeeking Alpha • 08/31/20
Fortress Biotech Announces Positive Topline Clinical Efficacy Results for CUTX-101, Copper Histidinate, for the Treatment of Menkes DiseaseGlobeNewsWire • 08/28/20
Fortress Biotech Announces $60 Million Loan Agreement with Oaktree Capital ManagementGlobeNewsWire • 08/28/20
Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley FBR on Tuesday, August 18 and Wednesday, August 19, 2020GlobeNewsWire • 08/12/20
Fortress Biotech Reports Second Quarter 2020 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 08/10/20
Fortress Biotech Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CUTX-101, Copper Histidinate, for the Treatment of Menkes DiseaseGlobeNewsWire • 07/31/20
Fortress Biotech Announces Publication of Study on Targeted Next Generation Sequencing for Newborn Screening of Menkes Disease in Molecular Genetics and Metabolism ReportsGlobeNewsWire • 07/29/20
Fortress Biotech to Present at the Raymond James Human Health Innovation ConferenceGlobeNewsWire • 06/15/20
Fortress Biotech Announces Publication of Study on Estimated Birth Prevalence of Menkes Disease in Molecular Genetics and Metabolism ReportsGlobeNewsWire • 06/11/20
Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform for the Treatment of Genetically Driven CancersGlobeNewsWire • 05/08/20
Fortress Biotech Announces Up to $5 Million Series A Cumulative Redeemable Perpetual Preferred Stock Repurchase ProgramGlobeNewsWire • 03/23/20
Fortress Biotech Announces Closing of Series A Preferred Stock Offering and Full Exercise of Over-Allotment OptionGlobeNewsWire • 02/24/20
Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes DiseaseGlobeNewsWire • 01/16/20
Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children’s Hospital Medical Center to Develop a Novel Treatment for Select CNS DisordersGlobeNewsWire • 12/23/19
Fortress Biotech to Participate in the 5th Annual Dawson James Small Cap Growth ConferenceGlobeNewsWire • 10/24/19